Related references
Note: Only part of the references are listed.GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma
Manish Charan et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma
Frank Milton Balis et al.
PEDIATRIC BLOOD & CANCER (2020)
GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells
Christian M. Seitz et al.
ONCOIMMUNOLOGY (2020)
Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors
Giulia Golinelli et al.
CANCER GENE THERAPY (2020)
Combined use of multiparametric flow cytometry and cytomorphology to enhance detection of neuroblastoma metastatic cells in bone marrow
Christine Manenq et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2020)
Disialoganglioside GD2 Expression in Pediatric Rhabdomyosarcoma: A Case Series and Review of the Literature
Amanda J. Saraf et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2019)
Positron Emission Tomography Detects In Vivo Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma
Elizabeth R. Butch et al.
CANCER RESEARCH (2019)
Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study
Suzanne Shusterman et al.
CLINICAL CANCER RESEARCH (2019)
The Promise of Anti-idiotype Revisited
Heinz Kohler et al.
FRONTIERS IN IMMUNOLOGY (2019)
Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
Dana L. Casey et al.
FRONTIERS IN ONCOLOGY (2019)
Gangliosides: The Double-Edge Sword of Neuro-Ectodermal Derived Tumors
Sumeyye Cavdarli et al.
BIOMOLECULES (2019)
CD171-and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
Lena Andersch et al.
BMC CANCER (2019)
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma
Xin Xu et al.
CLINICAL CANCER RESEARCH (2019)
High GD2 expression defines breast cancer cells with enhanced invasiveness
Maryam Mansoori et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2019)
A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
Wayne L. Furman et al.
CLINICAL CANCER RESEARCH (2019)
Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
Irina V. Kholodenko et al.
MOLECULES (2019)
Cytokine-induced killer cells/natural killer cells combined with anti-GD2 monoclonal antibody increase cell death rate in neuroblastoma SK-N-SH cells
Chi Zhang et al.
ONCOLOGY LETTERS (2019)
Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal
Becky Pennington et al.
PHARMACOECONOMICS (2019)
CARPETS: A Phase I study of the safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with GD2-positive metastatic melanoma and refractory solid tumors
Michael Brown et al.
CANCER RESEARCH (2019)
Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma
Wesley E. Barry et al.
CLINICAL CANCER RESEARCH (2019)
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
Michelle E. Keyel et al.
BIOLOGICS-TARGETS & THERAPY (2019)
Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
Frank Peinemann et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)
Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy
Tatjana Terzic et al.
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2018)
High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
Sarah A. Richman et al.
CANCER IMMUNOLOGY RESEARCH (2018)
ASC amino acid transporter 2, defined by enzyme-mediated activation of radical sources, enhances malignancy of GD2-positive small-cell lung cancer
Nobutoshi Esaki et al.
CANCER SCIENCE (2018)
Enhancement of malignant properties of human glioma cells by ganglioside GD3/GD2
Taiji Iwasawa et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series
Pranathi Ari et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2018)
Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, phase 2/3 study
M. J. Edelman et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas
Christopher W. Mount et al.
NATURE MEDICINE (2018)
Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma
Thitinee Vanichapol et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
Irina V. Kholodenko et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
GD2 as a circulating tumor biomarker (CTB) for neuroblastoma (NBL).
Frank M. Balis et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ganglioside GD3 synthase (GD3S), a novel cancer drug target
Jinyi Liu et al.
ACTA PHARMACEUTICA SINICA B (2018)
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Ruth Ladenstein et al.
LANCET ONCOLOGY (2018)
Differential roles of gangliosides in malignant properties of melanomas
Yuhsuke Ohmi et al.
PLOS ONE (2018)
CAR T Cell Therapy for Neuroblastoma
Rebecca M. Richards et al.
FRONTIERS IN IMMUNOLOGY (2018)
Humanized 3F8 Anti-G(D2) Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma A Phase 1 Clinical Trial
Brian H. Kushner et al.
JAMA ONCOLOGY (2018)
Anti-ganglioside GD2 monoclonal antibody synergizes with cisplatin to induce endoplasmic reticulum-associated apoptosis in osteosarcoma cells
Weihong Zhu et al.
PHARMAZIE (2018)
TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Hung C. Tran et al.
CLINICAL CANCER RESEARCH (2017)
Anti-GD2 immunotherapy for neuroblastoma
Sameer Sait et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Irinotecan-temozolomide with temsirolimus or dinutuximab Crosstafark in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Rajen Mody et al.
LANCET ONCOLOGY (2017)
Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer
Venkatrao Vantaku et al.
ONCOTARGET (2017)
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells
Amanda Tivnan et al.
ONCOTARGET (2017)
Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy
Julien Fleurence et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy
Zulmarie Perez Horta et al.
IMMUNOTHERAPY (2016)
Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
Jaume Mora
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
GD2/GD3 expression: Companion diagnostic for ganglioside-targeted immunotherapy against pediatric solid tumors.
Konstantin Dobrenkov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
GD2-specific chimeric antigen receptor T cells targeting retinoblastoma
Jatuporn Sujjitjoon et al.
CANCER RESEARCH (2015)
G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation
Saurabh Agarwal et al.
CANCER RESEARCH (2015)
Disialoganglioside GD2 as a therapeutic target for human diseases
Maya Suzuki et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology
Wenyong Tong et al.
PLOS ONE (2015)
Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells
Chun-Yen Tsao et al.
ONCOIMMUNOLOGY (2015)
Tumor gangliosides accelerate murine tumor angiogenesis
Yihui Liu et al.
ANGIOGENESIS (2014)
Ganglioside GD2 in reception and transduction of cell death signal in tumor cells
Igor I. Doronin et al.
BMC CANCER (2014)
Ganglioside GD2 as a Therapeutic Target for Antibody-Mediated Therapy in Patients With Osteosarcoma
Michael Roth et al.
CANCER (2014)
Perforin: an important player in immune response
Iwona Osinska et al.
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission
Brian H. Kushner et al.
CLINICAL CANCER RESEARCH (2014)
Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy
Mahiuddin Ahmed et al.
FEBS LETTERS (2014)
Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex
Sarah M. Cheal et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody
Nikolai Siebert et al.
PLOS ONE (2014)
GD2-Targeted Immunotherapy and Radioimmunotherapy
Konstantin Dobrenkov et al.
SEMINARS IN ONCOLOGY (2014)
Molecular recognition of gangliosides and their potential for cancer immunotnerapies
Ute Krengel et al.
FRONTIERS IN IMMUNOLOGY (2014)
Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies (vol 4, pg 114, 2014)
Nora Berois et al.
FRONTIERS IN ONCOLOGY (2014)
Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial.
Richard D. Carvajal et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Growth and Activation of Natural Killer Cells Ex Vivo from Children with Neuroblastoma for Adoptive Cell Therapy
Yin Liu et al.
CLINICAL CANCER RESEARCH (2013)
Detection of the GD2+/CD56+/CD45-Immunophenotype by Flow Cytometry in Cerebrospinal Fluids from a Patient with Retinoblastoma
Hongqiang Shen et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2013)
Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
Marie Vincent et al.
ONCOIMMUNOLOGY (2013)
The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting
S. Kailayangiri et al.
BRITISH JOURNAL OF CANCER (2012)
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis
Venkata Lokesh Battula et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission
Nai-Kong V. Cheung et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Analytical characterization of ch14.18 A mouse-human chimeric disialoganglioside-specific therapeutic antibody
Gopalan Soman et al.
MABS (2012)
Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements
Maha Zohra Ladjemi
FRONTIERS IN ONCOLOGY (2012)
Structures, Biosynthesis, and Functions of Gangliosides-an Overview
Robert K. Yu et al.
JOURNAL OF OLEO SCIENCE (2011)
A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity
Nidia Alvarez-Rueda et al.
PLOS ONE (2011)
Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
F. Navid et al.
CURRENT CANCER DRUG TARGETS (2010)
Shedding of GD2 ganglioside in patients with retinoblastoma
Jacques Portoukalian et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer
Lin-Chi Chen et al.
LUNG CANCER (2010)
The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions
Fiona A. Harding et al.
MABS (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
Gangliosides in cell recognition and membrane protein regulation
Pablo H. H. Lopez et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2009)
Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: Direct interaction of GM3 with VEGFR-2
Tae-Wook Chung et al.
GLYCOBIOLOGY (2009)
An aggressive bone marrow evaluation including immunocytology with GID2 for advanced retinoblastoma
Guillermo L. Chantada et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2006)
Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies - Roles of anoikis
W Aixinjueluo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma
T Simon et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Neuroblastoma: Biological insights into a clinical enigma
GM Brodeur
NATURE REVIEWS CANCER (2003)
An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-jun terminal kinase) activation
S Yoshida et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
Phase I study of chimeric human/murine anti-ganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation:: A Children's Cancer Group Study
MF Ozkaynak et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
